Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients

European Journal of Medical Research

Volumn 11, Issue 4, 2006, Pages 139-145

  Li, J ^a   Dahmen, Uta ^a   Beckebaum, S ^a   Cicinnati, V ^a   Valentin Gamazo, C ^a   Frilling, A ^a   Malago, M ^a   Broelsch, C E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adverse events; C2; Cyclosporine; Liver transplantation

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION COEFFICIENT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROTOXICITY; PARESTHESIA; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT OUTCOME; TREMOR; WEAKNESS;

ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 33646749295     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kahan BD. Cyclosporine: a powerful addition to the immunosuppressive armamentarium. Am J Kidney Dis 1984; 3:444.
2. Belitsky P, Levy GA, Johnston A. Neoral absorption profiling: an evolution in effectiveness. Transplant Proc 2000; 32:45S.
3. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73:S12.
4. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation 2002; 73:S19.
5. Levy GA. Neoral use in the liver transplant recipient. Transplant Proc 2000; 32:2S.
6. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15:279.
7. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73:953.
8. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72:1024.
9. Hesselink DA, van Dam T, Metselaar HJ, et al. The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. Transpl Int 2004; 17:495.
10. Teisseyre J, Markiewicz M, Drewniak T, et al. Switching cyclosporine blood concentration monitoring from C0 to C2 in children late after liver transplantation. Transplant Proc 2003; 35:2287.
11. Sterneck M, Zadeh KM, Groteluschen R, Broring D, Rogiers X, Fischer L. Clinical use of c2 monitoring in long-term liver transplant recipients. Transplant Proc 2002; 34:3304.
12. Barakat O, Peaston R, Rai R, Talbot D, Manas D. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients. Transplant Proc 2002; 34:1535.
13. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr post-dose levels in stable liver transplant patients. Transplantation 1998; 66:1621.
14. Langers P, Cremers SC, Den Hartigh J, et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transpl 2004; 10:183.
15. Cohen AJ, Stegall MD, Rosen CB, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8:916.
16. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004; 10:577.
17. Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69:1886.
18. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183:595.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31.
20. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9:126.
21. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13:313.
22. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation 2002; 73:S3.
23. Holt DW. Cyclosporin monitoring based on C2 sampling. Transplantation 2002; 73:840.
24. Neuberger J. Renal failure late after liver transplantation. Liver Transpl 2002; 8:922.
25. Levy GA, O'Grady C, Lilly LB, Grant D, Girgrah N, Greig PD. Conversion to C2 cyclosporine monitoring using Neoral immunosuppression in maintenance liver transplant patient: improvement in renal function and hypertension. Am J Transplant 2001; 1:310.
26. Canzanello VJ, Textor SC, Taler SJ, et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998; 4:328.
27. Varo E, Padin E, Otero E, et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. Transplant Proc 2002; 34:1553.